David A Armistead

Title: The Innovations of David A. Armistead

Introduction

David A. Armistead is a notable inventor based in Maynard, MA (US). He has made significant contributions to the field of immunology through his innovative work on immunosuppressive compounds. With a total of 2 patents, Armistead's inventions have the potential to impact medical treatments significantly.

Latest Patents

Armistead's latest patents focus on a novel class of immunosuppressive compounds that exhibit an affinity for the FK-506 binding protein (FKBP). These compounds, once bound to FKBP, inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity, which in turn inhibits T cell activation. This mechanism allows the compounds to be utilized as immunosuppressive drugs, effectively preventing or significantly reducing graft rejection in bone marrow and organ transplantations. Additionally, these compounds can be employed in the treatment of various autoimmune diseases in humans and other mammals.

Career Highlights

David A. Armistead is currently associated with Vertex Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work has been instrumental in the creation of therapies that address critical health challenges.

Collaborations

Armistead has collaborated with esteemed colleagues such as Joshua S. Boger and Harold V. Meyers, contributing to a rich environment of innovation and discovery.

Conclusion

David A. Armistead's contributions to immunology through his patents and collaborations highlight his role as a significant inventor in the field. His work not only advances scientific knowledge but also has the potential to improve patient outcomes in critical medical situations.